Jean-Pierre Rabs

List of Publications by Citations

15 papers	2,472 citations	11 h-index	18 g-index
18 ext. papers	2,900 ext. citations	6.2 avg, IF	3.38 L-index

#	Paper	IF	Citations
15	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nature Genetics*, **2003**, 34, 154-6	36.3	2025
14	Molecular spectrum of autosomal dominant hypercholesterolemia in France. *Human Mutation*, **2010**, 31, E1811-24	4.7	86
13	Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. *Human Mutation*, **2013**, 34, 83-7	4.7	84
12	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. *Circulation: Cardiovascular Genetics*, **2015**, 8, 823-31		76
11	Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. *Current Atherosclerosis Reports*, **2014**, 16, 439	6	72
10	Exome sequencing in suspected monogenic dyslipidemias. *Circulation: Cardiovascular Genetics*, **2015**, 8, 343-50		36
9	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). *Expert Opinion on Therapeutic Patents*, **2016**, 26, 1377-1392	6.8	18
8	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. *Atherosclerosis*, **2018**, 277, 334-340	3.1	18
7	Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?. *European Journal of Human Genetics*, **2018**, 26, 570-578	5.3	16
6	Familial hypercholesterolemia: experience from France. *Current Opinion in Lipidology*, **2018**, 29, 65-71	4.4	16
5	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. *Scientific Reports*, **2018**, 8, 1943	4.9	13
4	APOE gene variants in primary dyslipidemia. *Atherosclerosis*, **2021**, 328, 11-22	3.1	10
3	Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. *Medical Science Monitor*, **2021**, 27, e928784	3.2	1
2	APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia. *International Journal of Molecular Sciences*, **2022**, 23, 5792	6.3	0
1	A Simple RFLP-Based Method for Gene Multiplex Amplification and Determination of Hereditary Hemochromatosis-Causing Mutation C282Y and H63D Variant with Highly Sensitive Determination of Contamination. *BioMed Research International*, **2020**, 2020, 9396318	3	